MX369414B - Peptido. - Google Patents

Peptido.

Info

Publication number
MX369414B
MX369414B MX2015009085A MX2015009085A MX369414B MX 369414 B MX369414 B MX 369414B MX 2015009085 A MX2015009085 A MX 2015009085A MX 2015009085 A MX2015009085 A MX 2015009085A MX 369414 B MX369414 B MX 369414B
Authority
MX
Mexico
Prior art keywords
peptide
apitope
mog
myelin oligodendrocyte
oligodendrocyte glycoprotein
Prior art date
Application number
MX2015009085A
Other languages
English (en)
Other versions
MX2015009085A (es
Inventor
David Wraith
Original Assignee
Apitope Tech Bristol Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apitope Tech Bristol Limited filed Critical Apitope Tech Bristol Limited
Publication of MX2015009085A publication Critical patent/MX2015009085A/es
Publication of MX369414B publication Critical patent/MX369414B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a un péptido que es capaz de unirse a una molécula del MHC in vitro y de ser presentado a una célula T sin procesamiento del antígeno, en donde dicho péptido se selecciona de los siguientes péptidos de la glucoproteína de oligodendrocitos de la mielina (MOG), MOG 41-55 (SEQ ID NO: 1), 43-57 (SEQ ID NO: 2) , 44-58 (SEQ ID NO:3) y 45-59 (SEQ ID NO: 4), para usarse en el tratamiento y/o prevención de una enfermedad desmielinizante al unirse al MHC clase II en células que presenta antígeno (APCs) e inducir anergia y tolerancia de células T.
MX2015009085A 2013-01-15 2014-01-13 Peptido. MX369414B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1300684.6A GB201300684D0 (en) 2013-01-15 2013-01-15 Peptide
PCT/IB2014/058233 WO2014111840A2 (en) 2013-01-15 2014-01-13 Peptide

Publications (2)

Publication Number Publication Date
MX2015009085A MX2015009085A (es) 2016-02-16
MX369414B true MX369414B (es) 2019-11-07

Family

ID=47757995

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009085A MX369414B (es) 2013-01-15 2014-01-13 Peptido.

Country Status (16)

Country Link
US (2) US9862751B2 (es)
EP (1) EP2945966B1 (es)
JP (1) JP6347065B2 (es)
KR (1) KR102169902B1 (es)
CN (1) CN105121463B (es)
AU (1) AU2014206592B2 (es)
BR (1) BR112015016780A2 (es)
CA (1) CA2897655C (es)
GB (1) GB201300684D0 (es)
HK (1) HK1211596A1 (es)
IL (1) IL239871B (es)
MX (1) MX369414B (es)
RU (1) RU2675479C2 (es)
SG (1) SG11201505526TA (es)
WO (1) WO2014111840A2 (es)
ZA (1) ZA201504987B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN106986930B (zh) * 2017-04-14 2021-06-11 广东省生物资源应用研究所 一种诱导食蟹猴实验性自身免疫性脑脊髓炎动物模型的蛋白和应用
JP7419229B2 (ja) * 2017-08-14 2024-01-22 百明信康生物技術（浙江）有限公司 方法
GB201909774D0 (en) 2019-07-08 2019-08-21 Apitope Tech Bristol Limited Method

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006727A2 (en) * 1993-09-03 1995-03-09 Immulogic Pharmaceutical Corporation Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
EP0922057A1 (en) * 1996-03-28 1999-06-16 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
SE9703287D0 (sv) 1997-09-11 1997-09-11 Astra Ab Peptides
ES2338890T3 (es) 1999-03-12 2010-05-13 The Board Of Trustees Of The Leland Stanford Junior University Vacunacion por dna para el tratamiento de enfermedades autoinmunes.
IL132611A0 (en) 1999-10-27 2001-03-19 Yeda Res & Dev Synthetic genes and polypeptides and pharmaceutical compositions comprising them
JP2004500110A (ja) 2000-03-29 2004-01-08 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 自己反応性ｔ細胞による組織破壊をブロックする方法
HU229377B1 (hu) 2000-08-21 2013-11-28 Apitope Technology Bristol Ltd Tolerogén humán peptidek
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
EP2123669A1 (en) 2001-10-03 2009-11-25 The President and Fellows of Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
CA2614171C (en) 2001-10-03 2012-04-24 President And Fellows Of Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
IL146016A0 (en) 2001-10-17 2002-07-25 Yeda Res & Dev Synthetic peptides and dna sequences and compositions comprising them for treatment of multiple sclerosis
US7700572B2 (en) 2001-11-02 2010-04-20 Giuliani International, Ltd. SMAD7 inhibitors for the treatment of CNS diseases
PL214283B1 (pl) 2002-08-08 2013-07-31 Baylor College Medicine Sposób izolacji komórek T, sposób wytwarzania autologicznej szczepionki komórek T, autologiczna szczepionka komórek T, zastosowanie autologicznej szczepionki komórek T
AU2003279084A1 (en) 2002-09-25 2004-04-19 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
JP2008500006A (ja) 2003-05-21 2008-01-10 バイオテック トゥールス ソシエテ アノニム ペプチド複合体
AU2004288157B2 (en) 2003-09-05 2011-03-17 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
AU2011202900B2 (en) 2003-09-05 2012-08-02 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
WO2006057003A2 (en) 2004-11-29 2006-06-01 Yeda Research And Development Co. Ltd. Induction of neurogenesis and stem cell therapy in combination with copolymer 1
AU2012201067A1 (en) 2005-03-14 2012-03-15 B.G. Negev Technologies And Applications Ltd. Compositions of HSP60 peptides and viral antigens for vaccination and diagnosis
AU2006224216B2 (en) 2005-03-14 2011-12-08 B.G. Negev Technologies And Applications Ltd. Compositions of HSP60 peptides and viral antigens for vaccination and diagnosis
IL185932A (en) 2005-03-14 2014-02-27 Yeda Res & Dev Viral antigens, conjugates and preparations containing them, for vaccination and diagnosis
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
EP1931383A1 (en) 2005-09-28 2008-06-18 Cytos Biotechnology AG Interleukin-1 conjugates and uses thereof
EP1964574B1 (en) 2005-11-14 2016-09-07 Cellmid Limited Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
EP1969119B1 (en) 2005-11-17 2011-07-20 The Cleveland Clinic Foundation Multipotent neural stem cells
US7803364B2 (en) 2005-11-17 2010-09-28 The Cleveland Clinic Foundation Multipotent neural stem cells
WO2007094003A2 (en) 2006-02-15 2007-08-23 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
US20080317710A1 (en) 2006-02-22 2008-12-25 University Of Zurich Methods For Treating Autoimmune or Demyelinating Diseases
PL2420833T3 (pl) 2006-05-05 2016-03-31 Opexa Therapeutics Szczepionka z komórek T
AU2012202713B2 (en) 2006-05-31 2015-04-09 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
AU2012202776A1 (en) 2006-05-31 2012-05-31 Lpath, Inc. Novel Bioactive Lipid Derivatives, Immune-derived Moieties Reactive Thereto, and Methods of Making and Using Same
WO2007149982A2 (en) 2006-06-22 2007-12-27 The Brigham And Women's Hospital, Inc. Diagnosis of autoimmune disease
EP3170401B1 (en) 2006-10-25 2019-06-05 Revalesio Corporation Ionic aqueous fluid composition containing oxygen microbubbles
US8188218B2 (en) 2006-10-27 2012-05-29 University Of Kansas Bi-functional peptides for multiple sclerosis treatment and diagnosis
PL2087002T3 (pl) 2006-10-27 2015-02-27 Lpath Inc Kompozycje i sposoby do wiązania sfingozyno-1 fosforanu
US8263064B2 (en) 2007-06-04 2012-09-11 Rappaport Family Institute For Research In The Medical Sciences Method of suppressing disease severity of multiple sclerosis using chemokine CXC11
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
MX2010004698A (es) * 2007-10-31 2010-05-13 Apitope Technology Bristol Ltd Composicion.
WO2009101207A1 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Cd4+ t-cells with cytolytic properties
WO2010045265A1 (en) 2008-10-13 2010-04-22 Biovista, Inc. Compositions and methods for treating multiple sclerosis
BRPI0920430A2 (pt) 2008-10-22 2019-09-24 Revalesio Corp composições e métodos para tratar condições mediadas por metaloproteinase matriz 9 (mmp9)
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
US9267945B2 (en) 2008-11-12 2016-02-23 Yeda Research And Development Co. Ltd. Diagnosis of multiple sclerosis
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
CA2758738A1 (en) 2009-04-27 2010-11-04 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US8703711B2 (en) 2009-06-09 2014-04-22 Val-Chum, Limited Partnership Ninjurin-1 modulation and uses thereof
US8293468B2 (en) 2009-06-10 2012-10-23 Centre Hospitalier De L'université De Montréal MCAM modulation and uses thereof
CN102666581A (zh) 2009-08-31 2012-09-12 艾普利穆恩公司 用于抑制移植物排斥的方法和组合物
EP2510948B1 (en) 2009-12-09 2015-09-09 Mitsubishi Tanabe Pharma Corporation T cell activation inhibitor, pharmaceutical composition containing same, and screening method for t cell activation inhibiting substance
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
US20110189178A1 (en) 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
PL217128B1 (pl) 2010-08-02 2014-06-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Syntetyczne geny kodujące fragmenty peptydowe naturalnych białek mielinowych przeznaczone do wywoływania efektu tolerancji pokarmowej, fragmenty DNA zawierające te geny, sposób otrzymywania tych peptydów w układzie mikrobiologicznym (bakteryjnym) oraz ich zastosowanie medyczne
US10131875B2 (en) 2010-08-04 2018-11-20 Duke University Regulatory B cells and their uses
WO2012017439A2 (en) 2010-08-04 2012-02-09 Ramot At Tel-Aviv University Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
AU2011289172B2 (en) 2010-08-12 2015-09-24 Revalesio Corporation Compositions and methods for treatment of taupathy
EP2611827A4 (en) 2010-09-03 2014-03-19 Univ Oregon Health & Science RECEPTOR LIGANDS OF RECOMBINANT T LYMPHOCYTES WITH COVALENCE-RELATED PEPTIDES
US20130236473A1 (en) 2010-09-16 2013-09-12 Osaka University Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
EP2621522A2 (en) 2010-09-27 2013-08-07 China Agricultural University Combined antigen and dna vaccine for preventing and treating autoimmune diseases
WO2012045324A1 (en) 2010-10-07 2012-04-12 Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh Method for detecting a parkinson's disease and test system
EP2632955A1 (en) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
US20130309229A1 (en) 2011-01-28 2013-11-21 The United States Government As Represented By The Department Of Veterans Affairs Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases
US8685404B2 (en) * 2011-01-31 2014-04-01 Oregon Health & Science University Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
PL2727588T3 (pl) 2011-03-01 2019-04-30 Pharnext Terapia zaburzeń neurologicznych oparta na baklofenie i akamprozacie
JP5878447B2 (ja) 2012-09-12 2016-03-08 富士フイルム株式会社 ベースメイク化粧料
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide

Also Published As

Publication number Publication date
US9862751B2 (en) 2018-01-09
RU2015134356A (ru) 2017-02-22
WO2014111840A3 (en) 2014-10-30
WO2014111840A2 (en) 2014-07-24
CA2897655A1 (en) 2014-07-24
RU2675479C2 (ru) 2018-12-19
KR102169902B1 (ko) 2020-10-26
KR20150105365A (ko) 2015-09-16
JP2016505008A (ja) 2016-02-18
CA2897655C (en) 2023-04-04
IL239871B (en) 2018-12-31
US20180086802A1 (en) 2018-03-29
IL239871A0 (en) 2015-08-31
AU2014206592B2 (en) 2018-01-04
JP6347065B2 (ja) 2018-06-27
US10377800B2 (en) 2019-08-13
HK1211596A1 (en) 2016-05-27
EP2945966B1 (en) 2019-07-03
EP2945966A2 (en) 2015-11-25
BR112015016780A2 (pt) 2017-08-15
SG11201505526TA (en) 2015-08-28
GB201300684D0 (en) 2013-02-27
US20150353616A1 (en) 2015-12-10
CN105121463A (zh) 2015-12-02
ZA201504987B (en) 2017-11-29
MX2015009085A (es) 2016-02-16
CN105121463B (zh) 2020-11-27
AU2014206592A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
PH12018502429A1 (en) Antibody molecules for cancer treatment
MX2023014569A (es) Anticuerpos anti-sirpa.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
EA201590388A1 (ru) Способы лечения таупатии
MX342675B (es) Formulaciones estables para inyeccion parenteral de farmacos de peptido.
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX359449B (es) Conjugados de anticuerpo fármaco anti-cd70.
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
NZ715201A (en) Afucosylated anti-fgfr2iiib antibodies
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2023000204A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
MX2019015527A (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX369414B (es) Peptido.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX345534B (es) Compuestos y combinaciones farmaceuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.

Legal Events

Date Code Title Description
FG Grant or registration